As Senior Vice President & Chief Medical Officer of EyePoint Pharmaceuticals, Dario A. Paggiarino, M.D., leads Company Clinical Development programs and Medical Safety. He leverages more than 35 years of pharmaceutical industry experience with small molecules, biologics and devices/drug-device combinations across a variety of Therapeutic Areas. Prior to joining EyePoint in 2016, Dr. Paggiarino served as Senior Vice President and Chief Development Officer at lipid-targeted therapeutics company Lpath, where he advanced Phase I-II clinical programs in ophthalmology, oncology, and chronic pain. He also previously held the role of Vice President and Therapeutic Unit Head for Retinal Diseases at Alcon Laboratories, a division of Novartis, where he was responsible for advancing its retina pharmaceutical clinical development pipeline through regulatory approvals worldwide. Prior to that, Dr. Paggiarino served as Executive Director of Clinical Development and Medical Affairs at Pfizer Global R&D, with focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases, and medical responsibilities for Macugen®, the first anti-VEGF treatment approved for age-related macular degeneration. Earlier in his career, he held research and development positions at Angelini Pharmaceuticals as well as Pharmacia Global R&D, where he was Clinical Program Director of Ophthalmology with responsibilities over Xalatan® one of the leading glaucoma therapies in the world, and Tecnis® IOLs. Dr. Paggiarino holds an M.D. in Medicine and General Surgery from the University of Rome La Sapienza and has authored numerous scientific articles.